C4A Complement Pathway Decouples from C1Q in First-Episode Psychosis

The clinical management of first-episode psychosis remains a significant challenge for psychiatrists and primary care physicians, as standard antipsychotic therapies often fail to address the underlying neurobiological drivers of the disease. Emerging evidence suggests that a pro-inflammatory state and reduced antioxidant status are prevalent in these patients, potentially serving as targets for early intervention [1]. While peripheral markers like C-reactive protein and various interleukins are frequently elevated, the relationship between systemic inflammation and central nervous system changes remains complex [2]. Disruption of the blood-cerebrospinal fluid barrier (the physiological interface that regulates the movement of molecules between the systemic circulation and the brain) has been observed in a significant portion of patients with schizophrenia-spectrum disorders, particularly in males with severe positive symptoms [3]. Furthermore, the inflammatory hypothesis of schizophrenia links immune activation to aberrant glutamate-dopamine interactions and altered synaptic density [4]. A new study now offers specific insights into how components of the complement system (a part of the innate immune system that enhances the ability of antibodies and phagocytic cells to clear pathogens and damaged cells) behave differently within the brain and the blood during the initial stages of psychosis.